Atrium Therapeutics to Engage in Investor Conferences This September

Atrium Therapeutics to Participate in Investor Conferences

Atrium Therapeutics, Inc. (NASDAQ: RNA), a biopharmaceutical company focused on pioneering precision cardiology through RNA therapeutics, has announced its participation in several upcoming investor conferences this September. This participation represents a significant opportunity for the company to highlight its recent advancements and initiatives in developing targeted heart treatments.

Since its inception earlier this year, Atrium Therapeutics has demonstrated substantial progress in its mission to address cardiovascular diseases. Notably, the company received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning ATR-1072, aimed at treating PRKAG2 syndrome. Additionally, they received a No Objection Letter from Health Canada, further solidifying their commitment to bringing new therapies to market.

The list of investor conferences in which Atrium Therapeutics will be participating is as follows:

1. Wells Fargo 21st Annual Healthcare Conference
Date: September 8, 2026
Time: 8:00 a.m. ET
Location: Boston, MA

2. 2026 Cantor Global Healthcare Conference
Date: September 9, 2026
Time: 11:30 a.m. ET
Location: New York, NY

3. Morgan Stanley 24th Annual Global Healthcare Conference
Date: September 16, 2026
Location: New York, NY

Details regarding these events, including webcast information, will be accessible on Atrium's investor relations website, allowing interested parties to engage virtually or review subsequent recordings. The webcasts will be archived for at least 30 days following the presentations.

About Atrium Therapeutics

Atrium Therapeutics is revolutionizing the treatment landscape for patients with genetically driven cardiac conditions by delivering ribonucleic acid (RNA) therapeutics directly to the heart. The approval for their IND application concerning ATR-1072 progresses their first engagement in precision medicine, targeting PRKAG2 syndrome through a clinical trial known as Corventis Phase 1/2.

The company employs proprietary technology developed by Avidity Biosciences, which combines the selectivity of monoclonal antibodies with the precision of oligonucleotides. This innovative approach allows for the targeted delivery of small interfering RNA (siRNA), which holds the potential to dramatically improve treatment outcomes for individuals with cardiomyopathies.

In addition to ATR-1072, Atrium's pipeline includes ATR-1086, focusing on PLN cardiomyopathy, along with two other undisclosed targets intended to address rare cardiomyopathies.

Atrium advocates for transparency and accessibility regarding its research and development efforts, encouraging stakeholders to regularly visit their website for current updates on their clinical programs, disclosures, and investor presentations. These resources contribute to informing the public and investors about the advancements within the company and its ongoing commitment to improving heart health through innovative therapies.

They emphasize that while forward-looking statements are based on current estimates and intentions, the future outcomes of these initiatives can differ significantly, shaped by various risks and uncertainties as specified in previous filings with the Securities and Exchange Commission (SEC). This underscores the dynamic nature of the biopharmaceutical landscape.

For further information about Atrium Therapeutics, including engaging with their content on LinkedIn, visit their official website: Atrium Therapeutics.